Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Feb 8, 2018)
  • 8-K (Jan 8, 2018)
  • 8-K (Dec 22, 2017)
  • 8-K (Dec 6, 2017)
  • 8-K (Nov 13, 2017)
  • 8-K (Nov 9, 2017)

 
Other

Immunomedics 8-K 2015

Documents found in this filing:

  1. 8-K
  2. 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

Date of report (Date of earliest event reported): December 2, 2015

 

Immunomedics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware 000-12104 61-1009366
(State or Other Jurisdiction
of Incorporation)
(Commission File Number) (IRS Employer Identification No.)

 

300 The American Road, Morris Plains, New Jersey 7950
(Address of Principal Executive Offices) (Zip Code)

 

(973) 605-8200

(Registrant's telephone number,
including area code)

 

 

  Not applicable  
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

The Annual Meeting of Stockholders (the “Annual Meeting”) for Immunomedics, Inc. (the “Company”) was held at the Company’s headquarters, 300 The American Road, Morris Plains, New Jersey, on Wednesday, December 2, 2015. At the Annual Meeting, the following matters were submitted to a vote of stockholders:

 

  the election of six (6) directors to serve for a one-year term ending at the 2016 Annual Meeting of Stockholders, or until their respective successors are duly elected and qualified;
     
  the non-binding advisory vote to approve the compensation of the Company’s named executive officers;
     
  the ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2016.

 

At the close of business on October 7, 2015, the record date for the determination of stockholders entitled to vote at the Annual Meeting, there were 94,639,981 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. The holders of 80,834,945 shares of the Company’s common stock were represented in person or by proxy at the Annual Meeting, constituting a quorum.

 

With respect to the election of the director nominees for a one-year term ending at the 2016 Annual Meeting of Stockholders, the votes were as follows:

 

Name For Against Abstain Broker Non-
Votes
David M. Goldenberg 39,639,844 Shares 3,600,388 Shares 118,786 Shares 37,475,927 Shares
Cynthia L. Sullivan 40,312,159 Shares 2,890,273 Shares 156,586 Shares 37,475,927 Shares
Arthur S. Kirsch 40,985,294 Shares 2,243,191 Shares 130,533 Shares 37,475,927 Shares
Brian A. Markison 41,041,875 Shares 2,193,983 Shares 123,160 Shares 37,475,927 Shares
Mary E. Paetzold 40,639,888 Shares 2,571,349 Shares 147,781 Shares 37,475,927 Shares
Don C. Stark 40,448,287 Shares 2,792,230 Shares 118,501 Shares 37,475,927 Shares

 

The non-binding advisory votes with respect to approval of the compensation of the Company’s named executive officers were as follows:

 

For Against Abstain Broker Non-Votes
34,084,678 Shares 8,915,378 Shares 358,962 Shares 37,475,927 Shares

 

 

 

With respect to the ratification of the Company’s appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2016, the votes were as follows:

 

For Against Abstain
78,842,064 Shares 1,893,525 Shares 99,356 Shares

 

The foregoing votes reflect that all of the director nominees were elected for a one-year term ending at the 2016 Annual Meeting of Stockholders; the compensation of the Company’s named executive officers was approved by non-binding advisory votes; and KPMG LLP was ratified as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2016.

 

 

 

 

 

 

 

 

 

 

 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMMUNOMEDICS, INC.  
       
       
  By: /s/ Cynthia L. Sullivan  
  Name:  Cynthia L. Sullivan  
  Title: President and Chief Executive Officer

 

Dated: December 2, 2015

 

 

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki